<--- Back to Details
First PageDocument Content
Health economics / Healthcare quality / Immunosuppressants / Orphan drugs / Costs / Disease-modifying antirheumatic drug / Tocilizumab / Rituximab / Quality-adjusted life year / Rheumatoid arthritis / Etanercept / TNF inhibitor
Health economics
Healthcare quality
Immunosuppressants
Orphan drugs
Costs
Disease-modifying antirheumatic drug
Tocilizumab
Rituximab
Quality-adjusted life year
Rheumatoid arthritis
Etanercept
TNF inhibitor

TOCILIZUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS

Add to Reading List

Source URL: www.nicedsu.org.uk

Download Document from Source Website

File Size: 229,84 KB

Share Document on Facebook

Similar Documents

TOCILIZUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS REPORT BY THE DECISION SUPPORT UNIT Stephen Palmer, Mark Sculpher

DocID: 1s1AX - View Document

Medicine / Clinical medicine / Immunology / Immunosuppressants / RTT / Rheumatology / Orphan drugs / Specialty drugs / Tocilizumab / Autoimmunity / Rituximab / Rheumatoid arthritis

NOVEMBER 2015 TABLE OF CONTENTS INTRODUCTION

DocID: 1qUAB - View Document

Health economics / Healthcare quality / Immunosuppressants / Orphan drugs / Costs / Disease-modifying antirheumatic drug / Tocilizumab / Rituximab / Quality-adjusted life year / Rheumatoid arthritis / Etanercept / TNF inhibitor

TOCILIZUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS

DocID: 1pnYX - View Document

Immunosuppressants / Monoclonal antibodies / Immunology / Biotechnology / Immune system / TNF inhibitor / Infliximab / Tocilizumab / Adalimumab / Tumor necrosis factor alpha / Natalizumab / Etanercept

JULY 2016 TABLE OF CONTENTS INTRODUCTION

DocID: 1pejO - View Document

Monoclonal antibodies / Immunosuppressants / Immunology / Biotechnology / Immune system / Adalimumab / Tocilizumab / Infliximab / Monoclonal antibody therapy / Disease-modifying antirheumatic drug / TNF inhibitor / Rheumatology

TABLE OF CONTENTS INTRODUCTION 2

DocID: 1oMip - View Document